NME2P1

Across TCGA pan-cancer cohorts, NME2P1 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated NME2P1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NME2P1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NME2P1 expression acts as an unfavorable survival marker, although some lineages such as COAD and UVM show a favorable association.

ACC, MESO, and LGG are the cancer types where NME2P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.162	0.707	<.001	128	view →
MESO	OS	Median	All	0.438	0.646	.002	39	view →
LGG	OS	Tertile	All	0.735	0.895	<.001	38	view →
LUAD	DFS	Tertile	All	0.678	0.880	<.001	30	view →
KIRP	DFS	Tertile	IV	0.509	0.822	.010	29	view →
COAD	OS	Tertile	All	0.645	0.363	.001	26	view →
UCS	DFS	Median	IV	0.367	0.952	.001	24	view →
LIHC	OS	Quartile	All	0.541	0.739	.001	21	view →
UVM	DFS	Quartile	II,III,IV	0.725	0.388	.005	20	view →
CESC	OS	Tertile	IV	0.070	0.593	.022	12	view →
THCA	OS	Tertile	II,III,IV	1.000	0.347	.027	10	view →
KIRC	DFS	Tertile	All	0.722	0.866	.017	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

NME2P1–ACC (DFS)

Open the ACC breakdown →